EUVIMEDEUVIMED entdecken
CrossrefInfokarte

TH1/TH2 pattern of renal tissues in acute and chronic animal models treated with mesenchymal stem cells

Patricia Semedo, Carolina Gardini Palasio, Cassiano Donizetti Oliveira, Carla Quarim Feitoza, Giselle Martins Gonçalves, Pamella Mei Wang, Marcos Antonio Cenedeze, Alvaro Pacheco-Silva, Vicente de Paula Teixeira, Marlene Antônia dos Reis, Niels Olsen Saraiva Câmara

Brazilian Journal of Transplantation · 2007

DOI: 10.53855/bjt.v10i2.330 ↗
AbstractBibliografische Angaben

Abstract

Mesenchymal stem cell (MSC) therapy is a promising new therapy for kidney diseases. Many authors have been demonstrated that the MSC treatment leads to N improvement of the renal function in acute damaged models. However, the way it works still remains elusive. Purpose: To evaluate whether the renal protection provided by MSC administration seen in acute and chronic renal remnant damaged models involves modulation of the inflammation. Methods: MSC were attained from bone marrow of male Wistar rats. Female Wistar were subjected to ischemia-reperfusion damage by clamping renal pedicles for 1 hour. After a 6h reperfusion, 2.105 MSC were administrated i.v. in the chronic model. The nephrectomy models 5/6 were treated with 1.106 MSC administered i.v. after two weeks. Results: After a 24h reperfusion, MSC-treated animals presented a significant improvement of the renal function associated to decreased levels of IL-1β, IL-6 and TNF-α gene expression. Interestingly, the IL-4 mRNA expression increased in parallel. Furthermore, a higher expression of PCNA and an increase in the Bcl2/Bad ratio were seen in kidney tissues of MSC-treated animals. In the remnant model, this modulation in the cytokine pattern was sustained, despite a lack of amelioration of the renal dysfunction. Moreover, the expressions of TGF-β, MMP-9, TIMP-1 and Smad7 were not altered, although PAI-1 was significantly decreased. Conclusion: MSC therapy can indeed modulate the inflammatory response following acute and chronic renal injuries, accelerating the tubular repair; however, long-term outcomes seem not to be halted by this therapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →